| Identification | Back Directory | [Name]
SRI 37892 | [CAS]
1030769-75-5 | [Synonyms]
SRI 37892
Benzamide, 4-(1H-benzimidazol-1-yl)-N-[4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-2-thiazolyl]-
4-(1H-Benzo[d]imidazol-1-yl)-N-(4-(2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-2-yl)benzamide | [Molecular Formula]
C26H19N5O2S | [MOL File]
1030769-75-5.mol | [Molecular Weight]
465.53 |
| Hazard Information | Back Directory | [Uses]
SRI 37892 is a small molecule compound inhibitor of Frizzled protein 7 (Fzd7) with inhibitory activity against cancer cell proliferation (IC50=2μM). SRI 37892 significantly blocks Wnt/Fzd7 signaling. SRI 3789 can be used in the research of developing cancer therapeutic agents [1]. | [References]
[1] Zhang W, et al. Discovery of novel frizzled-7 inhibitors by targeting the receptor's transmembrane domain. Oncotarget. 2017 Sep 6;8(53):91459-91470. DOI:10.18632/oncotarget.20665 |
|
|